GlassScriptPhysician profile
Angela V Sutton
NPI 1265529291
$2,845.96
in general payments reported to CMS, 2019-2025
26 companies · $918 in 2025
The $918 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $98.31 · 2021: $21.93 · 2022: $263 · 2023: $261 · 2024: $569 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.02 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $579.52 | 2019-2025 | Omnipod |
| Abbott Laboratories | $436.28 | 2019-2025 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $204.14 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $193.88 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $162.99 | 2019-2020 | |
| Beta Bionics, INC. | $154.32 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $150.60 | 2025 | Twiist |
| Medtronic, INC. | $145.83 | 2023-2025 | Minimed 780g |
| Lilly USA, LLC | $111.07 | 2019-2025 | Jardiance, Trulicity, Mounjaro |
| Dexcom, INC. | $102.94 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $94.13 | 2019-2025 | Ozempic |
| Horizon Therapeutics Plc | $79.66 | 2022 | |
| Celgene Corporation | $66.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $58.31 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $52.30 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $37.79 | 2025 | Yorvipath |
| Valeritas, INC. | $31.52 | 2019 | |
| Mayne Pharma Commercial LLC | $28.05 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $27.04 | 2019 | |
| Ascensia Diabetes Care US INC. | $23.06 | 2025 | |
| Eisai INC. | $21.93 | 2021 | |
| Recordati_rare_diseases_inc. | $19.68 | 2023 | Isturisa, Signifor Lar |
| Bayer Healthcare Pharmaceuticals INC. | $17.44 | 2023 | |
| Merck Sharp & Dohme LLC | $16.64 | 2019 | |
| Amgen INC. | $15.95 | 2019 | |
| Cequr Corporation | $14.75 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.